

# Ernesto YagÃ¼e

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8316138/publications.pdf>

Version: 2024-02-01

25  
papers

901  
citations

471509

17  
h-index

552781

26  
g-index

26  
all docs

26  
docs citations

26  
times ranked

1487  
citing authors

#	ARTICLE	IF	CITATIONS
1	P-glycoprotein (MDR1) Expression in Leukemic Cells Is Regulated at Two Distinct Steps, mRNA Stabilization and Translational Initiation. <i>Journal of Biological Chemistry</i> , 2003, 278, 10344-10352.	3.4	112
2	miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 269-280.	2.5	80
3	Nicestrin regulates breast cancer stem cell properties and tumor growth in vitro and in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 16558-16563.	7.1	71
4	Structural insight into the TRIAP1/ PRELI-like domain family of mitochondrial phospholipid transfer complexes. <i>EMBO Reports</i> , 2015, 16, 824-835.	4.5	68
5	Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 461-474.	2.5	64
6	Ability to Acquire Drug Resistance Arises Early during the Tumorigenesis Process. <i>Cancer Research</i> , 2007, 67, 1130-1137.	0.9	53
7	Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer. <i>Cancer Letters</i> , 2018, 423, 47-59.	7.2	53
8	Activation of the MDR1 Upstream Promoter in Breast Carcinoma as a Surrogate for Metastatic Invasion. <i>Clinical Cancer Research</i> , 2004, 10, 2776-2783.	7.0	43
9	Frizzled-7-targeted delivery of zinc oxide nanoparticles to drug-resistant breast cancer cells. <i>Nanoscale</i> , 2019, 11, 12858-12870.	5.6	39
10	Sorcini silencing inhibits epithelial-to-mesenchymal transition and suppresses breast cancer metastasis in vivo. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 287-299.	2.5	36
11	Apoptosis inhibitor TRIAP1 is a novel effector of drug resistance. <i>Oncology Reports</i> , 2015, 34, 415-422.	2.6	33
12	Loss of O6-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells. <i>Biochemical Pharmacology</i> , 2013, 85, 186-196.	4.4	31
13	EP300 and SIRT1/6 Co-Regulate Lapatinib Sensitivity Via Modulating FOXO3-Acetylation and Activity in Breast Cancer. <i>Cancers</i> , 2019, 11, 1067.	3.7	29
14	Role of the highly structured 5' end region of MDR1 mRNA in P-glycoprotein expression. <i>Biochemical Journal</i> , 2007, 406, 445-455.	3.7	26
15	Novel Copper Complexes That Inhibit the Proteasome and Trigger Apoptosis in Triple-Negative Breast Cancer Cells. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1328-1335.	2.8	24
16	Progression-Related Loss of Stromal Caveolin 1 Levels Mediates Radiation Resistance in Prostate Carcinoma via the Apoptosis Inhibitor TRIAP1. <i>Journal of Clinical Medicine</i> , 2019, 8, 348.	2.4	23
17	miR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300. <i>Oncology Reports</i> , 2016, 35, 1170-1178.	2.6	22
18	Ruanjian Sanjie decoction exhibits antitumor activity by inducing cell apoptosis in breast cancer. <i>Oncology Letters</i> , 2017, 13, 3071-3079.	1.8	20

#	ARTICLE	IF	CITATIONS
19	GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 65-78.	2.5	18
20	Escape from stress granule sequestration: another way to drug resistance?. <i>Biochemical Society Transactions</i> , 2010, 38, 1537-1542.	3.4	12
21	FOXA1 is a determinant of drug resistance in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 317-326.	2.5	12
22	MicroRNA-495/TGF- $\beta$ 2/FOXC1 axis regulates multidrug resistance in metaplastic breast cancer cells. <i>Biochemical Pharmacology</i> , 2021, 192, 114692.	4.4	12
23	TMEFF2: A Transmembrane Proteoglycan with Multifaceted Actions in Cancer and Disease. <i>Cancers</i> , 2020, 12, 3862.	3.7	10
24	Oncogenic EP300 can be targeted with inhibitors of aldo-keto reductases. <i>Biochemical Pharmacology</i> , 2019, 163, 391-403.	4.4	5
25	Studies of proteasome inhibition and apoptosis induction in triple-negative breast cancer cells by novel amino acid-polypyridine-copper complex. <i>Applied Organometallic Chemistry</i> , 2019, 33, e5120.	3.5	3